Orthovita's Rhakoss enters spinal implant trials:
This article was originally published in Clinica
Orthovita is pressing ahead with plans to support an application for European approval of its Rhakoss synthetic bone spinal implant by starting clinical trials of the device. The trials are to include the study of the product in 75 patients undergoing cervical spinal fusion surgery. Rhakoss is made of Orthobone, a proprietary biomaterial developed by Malvern, Pennsylvania-based Orthovita. It is designed to provide a synthetic alternative to structural cadaver bone with unique bioactive and bone bonding characteristics, says the company.